Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma

被引：24

作者：

Hijiya, Naoki ^{[1
]}

Miyawaki, Michiyo ^{[2
]}

Kawahara, Katsunobu ^{[2
]}

Akamine, Shinji ^{[3
]}

Tsuji, Koh-Ichi ^{[4
]}

Kadota, Jun-Ichi ^{[5
]}

Akizuki, Shin'ichiro ^{[6
]}

Uchida, Tomohisa ^{[1
]}

Matsuura, Keiko ^{[1
]}

Tsukamoto, Yoshiyuki ^{[1
]}

Moriyama, Masatsugu ^{[1
]}

机构：

[1] Oita Univ, Fac Med, Dept Mol Pathol, Oita 8795593, Japan

[2] Oita Univ, Fac Med, Dept Surg 2, Oita 8795593, Japan

[3] Oita Prefectual Hosp, Dept Thorac Surg, Oita 8708511, Japan

[4] Oita Prefectual Hosp, Dept Pathol, Oita 8708511, Japan

[5] Oita Univ, Fac Med, Dept Internal Med 2, Oita 8795593, Japan

[6] Shin Beppu Hosp, Dept Pathol, Oita 8740833, Japan

来源：

HUMAN PATHOLOGY | 2008年 / 39卷 / 03期

关键词：

epidermal growth factor receptor; gefitinib; immunohistochemistry; phosphorylation; predictive marker;

D O I：

10.1016/j.humpath.2007.10.027

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Twenty-one cases of primary lung carcinoma were analyzed for correlations between the presence of somatic mutations of the epidermal growth factor receptor (EGFR) gene and the phosphorylation status of EGFR, which was analyzed by immunohistochemistry with antibodies recognizing the phosphorylated form of EGFR. Somatic mutations were detected in 11 (52.4%) of the 21 cases. Immunohistochemistry with an antibody recognizing EGFR phosphorylated at tyrosine (pEGFR-tyr) 992 and an antibody recognizing EGFR phosphorylated at tyrosine 1173 (PEGFR-tyr1173) revealed that 12 (57.1%) and 21 (100%) of the 21 cases were positive, respectively. Interestingly, the mutation status of the EGFR gene was strongly correlated with immunoreactivity for pEGFR-tyr992 (P = .0019). pEGFR-tyr992 immunoreactivity was significantly correlated with clinical responsiveness to gefitinib (P = .0011). These findings suggest that immunohistochemical evaluation with anti-pEGFR-tyr992 antibody is useful for prediction of responsiveness to gefitinib. (c) 2008 Published by Elsevier Inc.

引用

页码：316 / 323

页数：8

共 46 条

[1]

Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO

[2]

2-H

[3]

Amann J, 2005, CANCER RES, V65, P226

[4] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J].

Asahina, H. ;

Yamazaki, K. ;

Kinoshita, I. ;

Sukoh, N. ;

Harada, M. ;

Yokouchi, H. ;

Ishida, T. ;

Ogura, S. ;

Kojima, T. ;

Okamoto, Y. ;

Fujita, Y. ;

Dosaka-Akita, H. ;

Isobe, H. ;

Nishimura, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (08) :998-1004

[5] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[6] Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients [J].

Cortes-Funes, H ;

Gomez, C ;

Rosell, R ;

Valero, P ;

Garcia-Giron, C ;

Velasco, A ;

Izquierdo, A ;

Diz, P ;

Camps, C ;

Castellanos, D ;

Alberola, V ;

Cardenal, F ;

Gonzalez-Larriba, JL ;

Vieitez, JM ;

Maeztu, I ;

Sanchez, JJ ;

Queralt, C ;

Mayo, C ;

Mendez, P ;

Moran, T ;

Taron, M .

ANNALS OF ONCOLOGY, 2005, 16 (07) :1081-1086

[7] TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location [J].

Du, EZ ;

Goldstraw, P ;

Zacharias, J ;

Tiffet, O ;

Craig, PJ ;

Nicholson, AG ;

Weidner, N ;

Yi, ES .

HUMAN PATHOLOGY, 2004, 35 (07) :825-831

[8] Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay [J].

Endo, K ;

Konishi, A ;

Sasaki, H ;

Takada, M ;

Tanaka, H ;

Okumura, M ;

Kawahara, M ;

Sugiura, H ;

Kuwabara, Y ;

Fukai, I ;

Matsumura, A ;

Yano, M ;

Kobayashi, Y ;

Mizuno, K ;

Haneda, H ;

Suzuki, E ;

Iuchi, K ;

Fujii, Y .

LUNG CANCER, 2005, 50 (03) :375-384

[9] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[10] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

← 1 2 3 4 5 →